There's still hunger for 'blockbuster' biotech deals
August 25, 2014 at 10:58 AM EDT
Roche's $8.3 billion deal for InterMune is one of the few this year that returns to the traditional model of big pharma buying smaller biotech.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|